Last reviewed · How we verify
NCT03519061
Impact of Budesonide Irrigations on Patients With Chronic Rhinosinusitis and Impact on Sinus Surgery Rates
Phase 2, PHASE3 trial testing Budesonide in Chronic Sinus Infection. Withdrawn.
30 August 2019
Quick facts
| Lead sponsor | Kaiser Permanente |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 13 August 2019 |
| Primary completion | 30 August 2019 |
| Estimated completion | 1 October 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Budesonide (BUDESONIDE) — full drug profile →
Conditions studied
- Chronic Sinus Infection — all drugs for Chronic Sinus Infection →
- Chronic Sinusitis — all drugs for Chronic Sinusitis →
- Chronic Sinusitis - Ethmoidal, Posterior — all drugs for Chronic Sinusitis - Ethmoidal, Posterior →
- Chronic Sinus Congestion — all drugs for Chronic Sinus Congestion →
Sponsor
Kaiser Permanente — full company profile →
Who can join
18 and older, any sex, with Chronic Sinus Infection or Chronic Sinusitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is intended to assess the impact of a 90 day course of high volume budesonide irrigations for patients who have failed other medical therapy and assessing the impact of the budesonide irrigations on the need for sinus surgery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03519061
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Budesonide
Trials testing the same drug.
- NCT07528820 — Inflammatory Profiles, Histopathological Features, and Remodeling Factors in Chronic Rhinosinusitis With Nasal Polyps · NA · not yet recruiting
- NCT05878093 — Dupilumab in Chinese Adult Participants With CRSwNP · Phase 3 · completed
- NCT05562466 — A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Chil · Phase 3 · recruiting
- NCT06268301 — A Study to Determine the Effect Food Has on TAK-721 (Budesonide Oral Suspension) in the Body of Healthy Adults · Phase 1 · completed
- NCT05509933 — Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation · Phase 3 · recruiting
Other Kaiser Permanente trials
Trials by the same sponsor.
- NCT07522645 — Adherence to Dyslipidemia Therapy: Harnessing Evidence From Randomized Evaluations in AtheroSclerotic CardioVascular Dis · NA · not yet recruiting
- NCT07474038 — AI-Supported Cognitive Rehabilitation for Older Adults With Mild Cognitive Impairment · NA · enrolling by invitation
- NCT07467668 — Infusing Needed Iron to Target Insufficiency in Adults Treated for Evidence of Heart Failure · NA · not yet recruiting
- NCT07216859 — Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI) · NA · not yet recruiting
- NCT07264062 — MetSense Pilot and Feasibility · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03519061 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kaiser Permanente
- Last refreshed: 14 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03519061.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing